Update: An important period
Athersys is approaching an important period in the clinical development of MultiStem, its allogeneic stem cell therapy product. Enrolment in a Phase II study for ischaemic stroke is expected to complete within a couple of months and with a 90-day efficacy endpoint, headline results should be available in Q115. Positive data could re-rate the stock and ease concerns over the failed Phase II trial in ulcerative colitis earlier this year. Also in Q414 a Phase II study in acute myocardial infarction is due to start, and regulatory approval for a pivotal Phase II/III trial in GvHD could be secured.Athersys is a biotechnology company that is focused in the field of regenerative medicine. The company's MultiStem? cell therapy, a patented and proprietary allogeneic stem cell product, is its primary platform product and is in clinical development. The company's existing clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the existing standard of care is limited or inadequate for a number of patients. The company has a collaboration with HEALIOS K.K., to develop and commercialize MultiStem for the treatment of certain indications in Japan.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.